Efficacy and tolerability of BMS 650032 + peginterferon alfa-2a + ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2012
At a glance
- Drugs Asunaprevir; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
- 04 Apr 2011 New trial record
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.